Dilated cardiomyopathy: genetic determinants and mechanisms

EM McNally, L Mestroni - Circulation research, 2017 - Am Heart Assoc
Nonischemic dilated cardiomyopathy (DCM) often has a genetic pathogenesis. Because of
the large number of genes and alleles attributed to DCM, comprehensive genetic testing …

Organs-on-a-chip: a fast track for engineered human tissues in drug development

K Ronaldson-Bouchard, G Vunjak-Novakovic - Cell stem cell, 2018 - cell.com
Organs-on-a-chip (OOCs) are miniature tissues and organs grown in vitro that enable
modeling of human physiology and disease. The technology has emerged from converging …

Present Status of Brugada Syndrome: JACC State-of-the-Art Review

J Brugada, O Campuzano, E Arbelo… - Journal of the American …, 2018 - jacc.org
The Brugada syndrome is an inherited disorder associated with risk of ventricular fibrillation
and sudden cardiac death in a structurally normal heart. Diagnosis is based on a …

Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function

M Abulaiti, Y Yalikun, K Murata, A Sato, MM Sami… - Scientific reports, 2020 - nature.com
Human iPS cell (iPSC)-derived cardiomyocytes (CMs) hold promise for drug discovery for
heart diseases and cardiac toxicity tests. To utilize human iPSC-derived CMs, the …

Patient and disease–specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics

DT Paik, M Chandy, JC Wu, EH Ohlstein - Pharmacological reviews, 2020 - Elsevier
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …

Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association

K Musunuru, F Sheikh, RM Gupta… - Circulation: Genomic …, 2018 - Am Heart Assoc
Induced pluripotent stem cells (iPSCs) offer an unprece-dented opportunity to study human
physiology and disease at the cellular level. They also have the potential to be leveraged in …

Genome editing in induced pluripotent stem cells using CRISPR/Cas9

R Ben Jehuda, Y Shemer, O Binah - Stem Cell Reviews and Reports, 2018 - Springer
The development of the reprogramming technology led to generation of induced Pluripotent
Stem Cells (iPSC) from a variety of somatic cells. Ever since, fast growing knowledge of …

Use of human induced pluripotent stem cell–derived cardiomyocytes to assess drug cardiotoxicity

A Sharma, WL McKeithan, R Serrano, T Kitani… - Nature protocols, 2018 - nature.com
Cardiotoxicity has historically been a major cause of drug removal from the pharmaceutical
market. Several chemotherapeutic compounds have been noted for their propensities to …

Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients

H Wu, H Yang, JW Rhee, JZ Zhang… - European heart …, 2019 - academic.oup.com
Aims Diastolic dysfunction (DD) is common among hypertrophic cardiomyopathy (HCM)
patients, causing major morbidity and mortality. However, its cellular mechanisms are not …

Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent stem cells

N Ma, JZ Zhang, I Itzhaki, SL Zhang, H Chen… - Circulation, 2018 - Am Heart Assoc
Background: The progression toward low-cost and rapid next-generation sequencing has
uncovered a multitude of variants of uncertain significance (VUS) in both patients and …